Arena Capital Advisors’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Arena Capital Advisors’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-69,000	Closed	-$708K	–	65
2023 Q2	$708K	Hold	69,000	–	–	2.37%	11
2023 Q1	$698K	Hold	69,000	–	–	0.97%	19
2022 Q4	$688K	Hold	69,000	–	–	0.38%	47
2022 Q3	$671K	Hold	69,000	–	–	0.2%	80
2022 Q2	$669K	Sell	69,000 -257,328	-79%	-$2.5M	0.17%	92
2022 Q1	$3.17M	Buy	326,328 +250,000	+328%	+$2.41M	0.48%	71
2021 Q4	$749K	Buy	76,328 +14	+0%	+$137	0.07%	184
2021 Q3	$750K	Buy	+76,314	New	+$754K	0.06%	196

Arena Capital Advisors's DALS Position: Q3 2023 in Review

Arena Capital Advisors sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 69,000 shares — an estimated $708K sold.

Arena Capital Advisors first reported a position in DALS in Q3 2021 and held it in 8 quarters. The position peaked at $3.17M in Q1 2022. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Arena Capital Advisors reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Arena Capital Advisors sold 69,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $708K.
Arena Capital Advisors first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 8 quarters.
Arena Capital Advisors's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $3.17M in Q1 2022.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Arena Capital Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.